ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.
Anne Komé, PharmD
Advertisement
Anne Komé, PharmD, CPP, BCACP, CDCES, is a clinical pharmacist practitioner in the Endocrinology Clinic at the UNC Chapel Hill Medical Center.
Articles by Anne Komé, PharmD
Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.
ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care
2
Rituximab Matches Ocrelizumab in Head-to-Head MS Trial
3
GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH
4
FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch
5